MediWound Stock (NASDAQ:MDWD)


ForecastOwnershipChartTranscripts

Previous Close

$20.33

52W Range

$14.14 - $22.50

50D Avg

$20.35

200D Avg

$18.22

Market Cap

$215.40M

Avg Vol (3M)

$64.32K

Beta

0.32

Div Yield

-

MDWD Company Profile


MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel and bio-therapeutic solutions for tissue repair and regeneration. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

IL

Employees

111

IPO Date

Mar 20, 2014

Website

MDWD Performance


Latest Earnings Call Transcripts


Q1 25May 21, 25 | 8:30 AM
Q4 24Mar 19, 25 | 8:30 AM
Q3 24Nov 26, 24 | 8:30 AM

Peer Comparison


TickerCompany
IPSCCentury Therapeutics, Inc.
CLGNCollPlant Biotechnologies Ltd.
URGNUroGen Pharma Ltd.
KROSKeros Therapeutics, Inc.
SLGLSol-Gel Technologies Ltd.
MRUSMerus N.V.
GLMDGalmed Pharmaceuticals Ltd.
KMDAKamada Ltd.
VCELVericel Corporation